U.S. pharma giant copyright scrapped two experimental weight loss tablets past 12 months—a when-each day pill, lotiglipron, due to elevated liver enzymes as well as a two times-every day pill, danuglipron, resulting from sturdy Unwanted effects—but CEO Albert Bourla has said the company is determined to “play and gain” within the weight pro